{
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "document": "Zimmerman_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 1,
    "new_evidence_found": 0,
    "total_evidence": 1
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "relevance_explanation": "This statement directly addresses a key mechanism by which recombinant HA antigens produced using BEVS (such as RIV4) differ from egg-derived vaccines, supporting the claim that BEVS-produced antigens can induce broader and more effective immune responses due to the absence of egg-adaptive mutations."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}